Revenue
2018
2019
2020
2021
2022
2023
2024
2025
Travere Therapeutics, Inc. (TVTX)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2016
2017
2018
2019
2020
2021
2022
2023
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $490.7M | $233.2M | $145.2M | $109.5M | $131.8M | $198.3M | $175.3M | $164.2M | $154.9M | $133.6M | — | — | — | — | $0 | $0 |
| Research & development | $206.0M | $217.5M | $245.0M | $227.3M | $201.2M | $131.8M | $141.0M | $123.8M | $78.2M | $70.8M | $50.4M | $47.8M | $7.1M | $662,502 | — | — |
| Operating expenses | — | — | — | — | — | — | — | $244.3M | $208.7M | $191.8M | $150.6M | $108.0M | $24.8M | $30.3M | — | — |
| Operating income | −$62.8M | −$323.8M | −$388.1M | −$319.8M | −$199.4M | −$176.2M | −$137.4M | −$80.0M | −$53.8M | −$58.2M | −$50.7M | −$79.8M | −$24.8M | −$30.3M | — | — |
| EBITDAderived | −$2.1M | −$280.3M | −$349.6M | −$299.1M | −$186.7M | −$151.6M | −$117.0M | −$61.4M | −$36.0M | −$42.1M | −$37.4M | −$74.4M | −$24.6M | −$30.1M | — | — |
| Net income | −$25.5M | −$321.5M | −$111.4M | −$278.5M | −$180.1M | −$169.4M | −$146.4M | −$102.7M | −$59.7M | −$47.9M | $117.2M | −$110.9M | −$34.6M | −$30.3M | −$14,825 | −$23,022 |
| Basic EPSper diluted share | -$0.29 | -$4.08 | -$1.50 | -$4.37 | -$3.01 | -$3.56 | -$3.46 | -$2.54 | -$1.54 | -$1.29 | $3.49 | -$4.43 | -$2.44 | -$8.29 | — | — |
| Diluted EPSper diluted share | -$0.29 | -$4.08 | -$1.50 | -$4.37 | -$3.01 | -$3.56 | -$3.46 | -$2.54 | -$1.54 | -$1.29 | $3.17 | -$4.43 | -$2.44 | -$8.29 | — | — |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 12, 2026Form 4 · 10b5-1 | Baynes Roy D.Director | SellCommon Stock | 4.5K | $50.00 | $225.0K | 41.5K |
| Jun 12, 2026Form 4 · 10b5-1 | Coughlin TimothyDirector | SellCommon Stock | 10.0K | $50.07 | $500.7K | 56.3K |
| May 15, 2026Form 4 · 10b5-1 | Coughlin TimothyDirector | SellCommon Stock | 3.3K | $43.49 | $141.3K | 52.3K |
| May 6, 2026Form 4 · 10b5-1 | Cline Christopher R.CHIEF FINANCIAL OFFICER | SellCommon Stock | 310 | $43.95 | $13.6K | 118.7K |
| May 6, 2026Form 4 · 10b5-1 | Inrig JulaCHIEF MEDICAL OFFICER | SellCommon Stock | 311 | $43.95 | $13.7K | 113.2K |